anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Lung cancer is one of the most common malignant tumours. Patients are frequently at risk of frailty as lung cancer progresses. The meta-analysis aims to explore the impact of frailty on the long-term prognosis and the incidence of short-term chemotherapy toxicity in patients with lung cancer. This study was designed adhered to the criteria of Cochrane Handbook for Systematic Reviews. Systematic searches were performed on PubMed, Embase, Web of Science and Cochrane Library databases for relevant studies until December 2022. The outcome measures were overall survival, progression-free survival, chemotherapy toxicity and all-cause mortality. We then performed sensitivity analyses, subgroup analyses and evidence quality. This meta-analysis was performed using Review Manager V.5.4 software. Of the included studies, six were retrospective and five were prospective. There was a statistically significant difference between the frail and non-frail groups in overall survival (HR 2.27, 95% CI 1.24 to 4.15, p=0.008), all-cause mortality (HR 1.63, 95% CI 1.00 to 2.65, p=0.05) and chemotherapy toxicity (OR 3.73, 95% CI 1.99 to 7.00, p<0.0001). We conducted a sensitivity analysis, and the result was stable. The study revealed frail group had shorter survival and experienced more severe adverse effects than the non-frail group. Frailty affects the long-term prognosis and the incidence of short-term chemotherapy toxicity of patients with lung cancer. Consequently, medical professionals should focus on frailty screening in patients with lung cancer and implement active intervention measures. PROSPERO registration number is CRD42023398606.
The use of benzodiazepines, including ATIVAN Injection, exposes users to the risks of abuse, misuse, and addiction, which can lead to overdose or death. Abuse and misuse of benzodiazepines often (but not always) involve the use of doses greater than the maximum recommended dosage and commonly involve concomitant use of other medications, alcohol, and/or illicit substances, which is associated with an increased frequency of serious adverse outcomes, including respiratory depression, overdose, or death (see DRUG ABUSE AND DEPENDENCE, Abuse).

Before prescribing ATIVAN Injection and throughout treatment, assess each patient’s risk for abuse, misuse, and addiction. Use of ATIVAN Injection, particularly in patients at elevated risk, necessitates counseling about the risks and proper use of ATIVAN Injection along with monitoring for signs and symptoms of abuse, misuse, and addiction. Do not exceed the recommended dosing frequency; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants); and advise patients on the proper disposal of unused drug. If a substance use disorder is suspected, evaluate the patient and institute (or refer them for) early treatment, as appropriate.
Patients receive NRT patch daily for 8 weeks. Patients receive individual behavioral treatment sessions consisting of behavioral treatment strategies for smoking cessation and health education information over 45 minutes for 8 sessions.
The invention belongs to the field of nano-drug preparations, and particularly discloses an LPHF@DOX polymer nano-drug preparation and an anti-tumor application thereof. And loading the lauric acid-polyethyleneimine-cis-1, 2-cyclohexanedicarboxylic anhydride-folic acid LPHF polymer with doxorubicin to obtain the drug delivery system LPHF@DOX. After formation of a drug reservoir in the tumor tissue, HHPA undergoes acidolysis in an acidic environment to alter the solubility of the LPHF, releasing the lphf@dox nanoparticles. The LPHF@DOX can enhance the internalization of cells after being modified by FA. The drug reservoir as a deposit is believed to induce tumor tissue embolism, further facilitating the liberation of the drug feeding system from the drug reservoir to provide positive feedback drug therapy, significantly improving the toxic side effects of the drug and enhancing its bioavailability. The drug delivery system can be used as an anti-tumor preparation, and has great research value and application prospect in cancer treatment.
A double-stranded  cDNA molecule  which  includes  DNA encoding human manganese superoxide dismutase has been created. The sequence of one strand of a double-stranded DNA   molecule    which   encodes  human  manganese superoxide dismutase has been discovered. Such molecules may be introduced in prokaryotic, e.g., bacterial, or eucaryotic, e.g., yeast or mammalian, cells and the resulting cells cultured or grown under suitable conditions so as to produce human manganese superoxide dismutase, human manganese superoxide dismutase analogs or human manganese superoxide dismutase mutants which may then be recovered. By this invention, human manganese superoxide dismutase gene fragments from various plasmids may be ligated to yield a complete genomic human  manganese  superoxide  dismutase  gene  fragment. Human manganese superoxide dismutase, analogs,  or mutants  may  be  used  to  catalyze  the  reduction  of superoxide  radicals,  reduce reperfusion  injury, prolong the survival time of isolated organs, or treat inflammations.        The invention also concerns a method of producing enzy enzymatically active human manganese superoxide dismutase compounds in a bacterial cell which contains and is capable  of  expressing  a  DNA sequence  encoding  the superoxide dismutase compound by maintaining the bacterial cell under suitable conditions and in a suitable production medium. The production medium is supplemented with an amount of Mn++ so that the concentration of Mn++ in the medium is greater than about 2 ppm. Genomic manganese superoxide dismutase DNA should also be capable of expression in eucaryotic cells under suitable conditions.               This invention also concerns a method of recovering purified enzymatically active manganese superoxide dismutase, analogs or mutants from bacterial cells. It should also be possible to recover manganese SOD from genomic manganese superoxide dismutase DNA expressed in eucaryotic cells using similar methods.               The invention further concerns uses of the human manganese superoxide dismutase, human manganese superoxide dismutase analogs or human manganese superoxide dismutase mutants, various new analogs, compositions of the compounds and methods of treating various disorders using these compositions.
PURPOSE:To make possible the easy and quick quantitative determination and measurement of a labeling material by immobilizing a material having affinity to an antigen to a solid phase then adding a complement constituting component conjugated with the antigen and labeling material, etc. thereto to effect reaction and removing the non-conjugated matter. CONSTITUTION:The material having affinity to the antigen, for example, the substrate of enzyme or inhibitor, etc. are immobilized to the solid phase. Cleaning, etc. of the solid phase are thus made easy unlike the liquid phase. An antigen to be examined is then added to the material having affinity to the immobilized antigen to conjugate the antigen with the material having affinity to the antigen. The complement constituting component conjugated with the labeling material is further added to the conjugate. The labeling material such as a dye which permits easy measurement is selected. An antibody is further added thereto according to need to bring the conjugate into reaction. The conjugate consisting of the material having affinity to the antigen, the antigen, the complement constituting component conjugated with the labeling material, etc. is immnobilized to the solid phase and therefore the unconjugated complement constituting component and reaction inhibiting material are easily removed by cleaning. The labeling material of the conjugate adsorbed to the solid phase is then quantiatively determined. The efficiency of the measurement is thus improved and the measurement of the antigen quantity with high accuracy is made possible.
Hearing impairment has a significant impact on individual quality of life and stresses community resources. In the last two decades cochlear implantation has developed into the new standard of care for severe to profound haring loss. Recent studies have shown bilateral implantation improves sound localization and understanding of speech in noise. For children, this is seen as a significant benefit. As we begin to offer bilateral cochlear implants to a growing number of children it would be in our patient's best interest to evaluate whether or not this may cause balance impairment. We will evaluate the balance scores of children with bilateral cochlear implants, and compare their results to unilaterally implanted children and a hearing impaired population, with the Bruininks-Oseretsky Test 2nd ed (BOT2). In addition we will take a small group of unilaterally implanted patients and test them before and after a contralateral cochlear implant as a prospective study group.
The menopausal transition is a complex neuroendocrine aging process affecting brain structure and metabolic function. Such changes are consistent with neurological sequelae noted following the menopausal transition, including cognitive deficits. Although studies in rodent models of the menopause revealed changes in learning and memory, little is known about the structural and metabolic changes in the brain regions serving the cognitive function in these models. The administration 4-vinylcyclohexene diepoxide (VCD) in laboratory animals results in follicular depletion, and thus, is a powerful translational tool that models the human menopause. In the studies presented here, we evaluated behavior, brain structure, and metabolism in young female rats administered with either VCD or vehicle for 15 days across the early, mid, and post-follicular depletion states at 1-, 2-, and 3-months post-final injection, respectively. Additionally, we evaluated the serum hormonal profile and ovarian follicles based on the estrous cycle pattern. Positron emission tomography (PET) was utilized to determine regional brain glucose metabolism in the hippocampus, medial prefrontal cortex, and striatum. Subsequently, the rats were euthanized for ex-vivo magnetic resonance imaging (MRI) to assess regional brain volumes. VCD-induced rats at the post-follicular depleted time points had diminished spatial learning and memory as well as reduced hippocampal glucose uptake. Additionally, VCD-induced rats at post-follicular depletion time points had marked reductions in estradiol, progesterone, and anti-mullerian hormone with an increase in follicle-stimulating hormone. These rats also exhibited fewer ovarian follicles, indicating that substantial ovarian function loss during post-follicular time points impairs the female rats' spatial learning/memory abilities and triggers the metabolic changes in the hippocampus.
AIM: Optimal care for patients with kidney failure reduces the risks of adverse health outcomes, including cardiovascular events and death. We evaluated data from the third iteration of the International Society of Nephrology Global Kidney Health Atlas (ISN-GKHA) to assess the capacity for quality service delivery for kidney failure care across countries and regions.
METHOD: We explored the quality of kidney failure care delivery and the monitoring of quality indicators from data provided by an international survey of stakeholders from countries affiliated with the ISN from July to September 2022.
RESULTS: One hundred and sixty seven countries participated in the survey, representing about 97.4% of the world's population. In countries where haemodialysis (HD) was available, 81% (n = 134) provided standard HD sessions (three times weekly for 3-4 h per session) to patients. Among countries with peritoneal dialysis (PD) services, 61% (n = 101) were able to provide standard PD care (3-4 exchanges per day). In high-income countries, 98% (n = 62) reported that >75% of centers regularly monitored dialysis water quality for bacteria compared to 28% (n = 5) of low-income countries (LICs). Capacity to monitor the administration of immunosuppression drugs was generally available in 21% (n = 4) of LICs, compared to 90% (n = 57) of high-income countries. There was significant variability between and within regions and country income groups in reporting the quality of services utilized for kidney replacement therapies.
CONCLUSION: Quality assurance standards on diagnostic and treatment tools were variable and particularly infrequent in LICs. Standardization of delivered care is essential for improving outcomes for people with kidney failure.
PURPOSE:To obtain the subject inhibiting agent useful as a drug, by using a compound such as 6-(3,7,11,15-tetramethyl-2,6,10,14-hexadecatetraenyl)-1,2,4- trihydroxybenzene as an active component. CONSTITUTION:The objective agent contains a compound of formula (1-4 of R<1>, R<2>, R<3>, R<4> and R<5> are hydroxy, alkoxy, aralkyloxy or acyloxy and the others are H or alkyl) as an active component. It is usually used in the form of a drug preparation in combination with a carrier for preparation. Some of the compounds of formula are known, however, the compounds include novel compounds. It can be synthesized e.g. by reacting a phenol derivative with 3,7,11,15-tetramethyl-2,6,10,14-hexadecatetraenyl bromide in the presence of NaH in a solvent and reacting the reaction product with a Lewis acid.
Ovarian cancer is the leading cause of gynecologic cancer death. Among the most innovative anti-cancer approaches, the genetic concept of synthetic lethality is that mutations in multiple genes work synergistically to effect cell death. Previous studies found that although vaccinia-related kinase-1 (VRK1) associates with DNA damage repair proteins, its underlying mechanisms remain unclear. Here, we found high VRK1 expression in ovarian tumors, and that VRK1 depletion can significantly promote apoptosis and cell cycle arrest. The effect of VRK1 knockdown on apoptosis was manifested by increased DNA damage, genomic instability, and apoptosis, and also blocked non-homologous end joining (NHEJ) by destabilizing DNA-PK. Further, we verified that VRK1 depletion enhanced sensitivity to a PARP inhibitor (PARPi), olaparib, promoting apoptosis through DNA damage, especially in ovarian cancer cell lines with high VRK1 expression. Proteins implicated in DNA damage responses are suitable targets for the development of new anti-cancer therapeutic strategies, and their combination could represent an alternative form of synthetic lethality. Therefore, normal protective DNA damage responses are impaired by combining olaparib with elimination of VRK1 and could be used to reduce drug dose and its associated toxicity. In summary, VRK1 represents both a potential biomarker for PARPi sensitivity, and a new DDR-associated therapeutic target, in ovarian cancer.
FIELD: medicine.SUBSTANCE: group of inventions relates to medicine, specifically to computerized methods for non-invasive detection of carbohydrate metabolism disorders (CMD) by cardiac electrocardiogram (ECG), population screening for detecting individuals with CMD signs by their ECG, as well as monitoring the level of the patient's CMD by ECG. Heart is considered as an open non-linear self-oscillation system characterized by Fermi-Pasta-Ulam (FPU) self-return, and the ECG is a representation of a FPU automatic return. ECG is removed. Fourier transform of the recorded ECG is performed to obtain an amplitude Fourier spectrum. Fourier amplitude spectrum is discretised to obtain discrete form of initial form of Fourier amplitude spectrum (DECG). DECG is analysed by computer processing to detect the presence/absence of the cardiac CMD by establishing the similarity/difference with the DECG of the patients with the CMD from an annotated sample of ECG and DECG of the healthy patients from the annotated ECG sample. Presence of similarity of analysed DECG with DECG of patients with CMD and absence of similarity with DECG of healthy patients is a sign of CMD. Screening method further includes setting sensitivity targets and specificity for determining the minimum required number of ECG of one person being tested and a threshold value of the number of ECG with signs of an CMD for each age group of observation, exceeding which the presence of an CMD is recognized in the patients of the group. Population is screened by ECG data extraction and processing. Results are statistically analysed by determining from the minimum required ECG number of one analysed ECG count with the CMD feature and comparing it with the preset threshold value. Monitoring method additionally involves accumulation in the database of the sequence of ECG recorded marked with patient identifiers. Degree of difference of the analysed DECG from the DECG of healthy people is calculated and used as an integral parameter of the CMD. Time variation of the level of the patient's CMD of the observed patient is evaluated by measuring the time-varying integral index. Level of the CMD is predicted on the basis of the "observation history", which is the recorded changes in time of previous values of the integral index.EFFECT: higher accuracy of assessing the patient's cardiac state for more qualitative detection of CMD by ECG, as well as reducing the time for diagnosing, screening the population and monitoring the level of the CMD.7 cl, 2 tbl, 4 ex, 7 dwg
Early recognition of bloodstream infection (BSI) in infants can be difficult, as symptoms may be non-specific, and culture can take up to 48 h. As a result, many infants receive unneeded antibiotic treatment while awaiting the culture results. In this study, we aimed to develop a model that can reliably identify infants who do not have positive blood cultures (and, by extension, BSI) based on the full blood count (FBC) and C-reactive protein (CRP) values. Several models (i.e. multivariable logistic regression, linear discriminant analysis, K nearest neighbors, support vector machine, random forest model and decision tree) were trained using FBC and CRP values of 2693 infants aged 7 to 60 days with suspected BSI between 2005 and 2022 in a tertiary paediatric hospital in Dublin, Ireland. All models tested showed similar sensitivities (range 47% - 62%) and specificities (range 85%-95%). A trained decision tree and random forest model were applied to the full dataset and to a dataset containing infants with suspected BSI in 2023 and showed good segregation of a low-risk and high-risk group. Negative predictive values for these two models were high for the full dataset (> 99%) and for the 2023 dataset (> 97%), while positive predictive values were low in both dataset (4%-20%).   Conclusion: We identified several models that can predict positive blood cultures in infants with suspected BSI aged 7 to 60 days. Application of these models could prevent administration of antimicrobial treatment and burdensome diagnostics in infants who do not need them. What is Known: • Bloodstream infection (BSI) in infants cause non-specific symptoms and may be difficult to diagnose. • Results of blood cultures can take up to 48 hours. What is New: • Machine learning models can contribute to clinical decision making on BSI in infants while blood culture results are not yet known.
Standard 2-year carcinogenicity studies in animals have not been performed. In Fischer 344 rats, a 12-month repeat-dose toxicity study was conducted with insulin lispro at subcutaneous doses of 20 and 200 units/kg/day (approximately 3 and 32 times the human subcutaneous dose of 1 unit/kg/day, based on units/body surface area). Insulin lispro did not produce important target organ toxicity including mammary tumors at any dose. 

Insulin lispro was not mutagenic in the following genetic toxicity assays: bacterial mutation, unscheduled DNA synthesis, mouse lymphoma, chromosomal aberration and micronucleus assays. 

Male fertility was not compromised when male rats given subcutaneous insulin lispro injections of 5 and 20 units/kg/day (0.8 and 3 times the human subcutaneous dose of 1 unit/kg/day, based on units/body surface area) for 6 months were mated with untreated female rats. In a combined fertility, perinatal, and postnatal study in male and female rats given 1, 5, and 20 units/kg/day subcutaneously (0.2, 0.8, and 3 times the human subcutaneous dose of 1 unit/kg/day, based on units/body surface area), mating and fertility were not adversely affected in either gender at any dose.
Narrative Exposure Therapy Narrative Exposure Therapy (NET) is a brief manualized trauma-focussed psychotherapeutic treatment and will be performed according to the manual of Schauer et al., 2011. In NET, traumatic experiences are worked through and placed in the context of the entire life story.
OBJECTIVE: The intrauterine balloon tamponade (IUBT) is one of the major tool to manage the postpartum hemorrhage (PPH). Previous studies identified factors predicting IUBT failure regardless the mode of delivery. Our aim was to determine if IUBT predictive failure can be determined regarding the mode of delivery.
MATERIALS AND METHODS: This was a retrospective cohort study among women who had IUBT secondary to severe PPH after vaginal or cesarean delivery from 2012 until 2021 at Lille (France). We compared 2 groups: success or failure of the IUBT, which was defined as the need of additional invasive procedures (uterine embolization or surgical procedure).
RESULTS: We included 238 women, 83 who underwent cesarean and 155 vaginal delivery. The overall success of the IUBT was 78% (80% for vaginal delivery and 75% for cesarean delivery). In the vaginal delivery group with failed IUBT, coagulopathies were significantly more frequent (84.2 vs. 33.3% P=<0.001) with higher estimated blood loss at the use of the IUBT (1865.8 vs. 1580.8mL, P=0.015) compared with the vaginal delivery group with success of IUBT. In the cesarean delivery group, none factor was significant between the two groups.
CONCLUSION: It is possible to identify predictors of IUBT failure in case of vaginal delivery. In contrast, in case of cesarean delivery, there is no apparent predictive facto. It could be interesting to validate our findings in a multicentric study.
FIELD: organic chemistry, pharmacy. SUBSTANCE: invention proposes derivatives of ethanolamine of the general formula (I)   where R 1  - phenyl, naphthyl, indalyl, pyridyl, benzofuranyl, benzodioxalyl; R 2  - halogen atom, nitro-group and others; R 3  - hydrogen atom, benzyl and others; n = 0-3. Method of synthesis of compounds of the formula (I) involves an interaction of compound of the formula (II):   with compound of the formula (III)  . Invention proposes also a pharmcomposition containing an effective amount of compounds of the formula (I) in combination with a pharmaceutically acceptable nontoxic carrier or vehicle that can be used for treatment and/or prophylaxis of human or animals with uresis disorder, spasms or increased peristalsis of gastroenteric tract. EFFECT: improved method of synthesis, enhanced effectiveness. 8 cl, 32 ex